Among 25 people with Graves' disease whose TSH levels were undetectable at the start, batoclimab injections led to a measurable rise in TSH by week 6, indicating the pituitary gland began to regain control over thyroid activity.
Claim Context
In 25 patients with Graves' disease, batoclimab treatment was associated with a mean increase of 0.13 mIU/L in thyroid-stimulating hormone (TSH) by week 6, with TSH being unmeasurable at baseline in all participants.
“A clinically relevant increase in mean (SD) TSH serum level, which was unmeasurable at baseline, was observed by Week 6 (mean [SD] change, 0.13 mIU/L; nominal p=0.04).”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether batoclimab consistently restores TSH levels to normal range in Graves' disease across multiple randomized trials, accounting for baseline TSH suppression severity.
A systematic review and meta-analysis of all randomized, double-blind, placebo-controlled trials of batoclimab in Graves' disease, including at least 500 participants, with primary outcome being proportion achieving TSH >0.4 mIU/L at 12 weeks, stratified by baseline TSH suppression.
Whether batoclimab causes a greater increase in TSH compared to placebo in patients with Graves' disease and undetectable baseline TSH.
A double-blind, placebo-controlled, multicenter trial of 150 adults with Graves' disease and baseline TSH <0.1 mIU/L, randomized 1:1 to batoclimab (680 mg then 340 mg weekly) or placebo for 24 weeks, with primary endpoint being TSH >0.4 mIU/L at week 6.
Whether TSH recovery after batoclimab is sustained over 1–2 years and correlates with reduced relapse rates.
A prospective cohort study of 300 Graves' disease patients treated with batoclimab, measuring TSH levels at baseline, 6, 12, 18, and 24 months, and tracking relapse (TSH <0.4 mIU/L with elevated FT3/FT4) after ATD discontinuation.
Whether the magnitude of TSH increase after batoclimab predicts likelihood of sustained euthyroidism without ATD.
A case-control study comparing 50 patients who maintained euthyroidism for ≥12 months after batoclimab to 50 who relapsed, assessing the magnitude of TSH increase at week 6 as a predictor.
The proportion of patients on batoclimab with TSH >0.4 mIU/L at a single time point in clinical practice.
A cross-sectional survey of 500 patients with Graves' disease currently on batoclimab, measuring current TSH level and ATD status at a single time point.